subject area of
- A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma Academic Article
- A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design Academic Article
- A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35 Academic Article
- A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant Academic Article
- Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells Academic Article
- An HLA-A2 polyepitope vaccine for melanoma immunotherapy Academic Article
- Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guerin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma Academic Article
- Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients Academic Article
- CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients Academic Article
- Cancer vaccines: Where are we going? Academic Article
- Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells Academic Article
- Characterization of antigen-specific CD8+ T lymphocyte responses in skin and peripheral blood following intradermal peptide vaccination Academic Article
- Clinical promise of tumour immunology Academic Article
- Current Status of Veterinary Vaccines Academic Article
- Development of a novel, quantitative protein microarray platform for the multiplexed serological analysis of autoantibodies to cancer-testis antigens Academic Article
- Directions in the immune targeting of cancer: Lessons learned from the cancer-testis Ag NY-ESO-1 Academic Article
- Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1 Academic Article
- Evolving role of tumor antigens for future melanoma therapies Academic Article
- Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients’ sera using short overlapping peptides and full-length recombinant protein Academic Article
- Functional and Structural Characteristics of NY-ESO-1-related HLA A2-restricted Epitopes and the Design of a Novel Immunogenic Analogue Academic Article
- HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan Academic Article
- Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel Academic Article
- ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II Academic Article
- Immunodominance and Immunodomination: Critical Factors in Developing Effective CD8+ T‐Cell–Based Cancer Vaccines Book
- Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ Academic Article
- Immunotherapy of melanoma: Targeting defined antigens Academic Article
- Influenza A Infection Enhances Cross-Priming of CD8+ T Cells to Cell-Associated Antigens in a TLR7- and Type I IFN-Dependent Fashion Academic Article
- Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy Academic Article
- Lentivector immunization induces tumor antigen‐specific B and T cell responsesin vivo Academic Article
- Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIX (TM) vaccine in patients with advanced melanoma Academic Article
- Mannan-MUC1-Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma Academic Article
- Melanoma vaccines: developments over the past 10 years Academic Article
- NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors Academic Article
- Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens Academic Article
- Perspective: cancer vaccines in the era of immune checkpoint blockade Academic Article
- Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery Academic Article
- Prostate cancer immunology - An update for urologists Academic Article
- Rational approaches to human cancer immunotherapy Academic Article
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis Academic Article
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans Academic Article
- Recombinant NY‐ESO‐1 Cancer Antigen: Production and Purification under cGMP Conditions Academic Article
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma Academic Article
- Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors Academic Article
- T Cell Determinants Incorporating β-Amino Acid Residues Are Protease Resistant and Remain Immunogenic In Vivo Academic Article
- T cells recognizing a 11mer influenza peptide complexed to H-2D(b) show promiscuity for peptide length Academic Article
- Targeted therapy of renal cell carcinoma: Synergistic activity of cG250-TNF and IFNg Academic Article
- Telomerase in cancer immunotherapy Academic Article
- The Efficacy of Epidermal Growth Factor Receptor-Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization Academic Article
- The humoral immune response to head and neck cancer antigens as defined by the serological analysis of tumor antigens by recombinant cDNA expression cloning. Academic Article
- The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases Academic Article
- The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Academic Article
- The therapeutic benefit of bacterial membrane vesicles Academic Article
- Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1 Academic Article
- Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery Academic Article
- Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma Editorial Article
- Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Academic Article